New pharmaceutical candidate Lu AA37096 enters Lundbeck's development pipeline

07-Jan-2008

Lundbeck has initiated phase I clinical studies with Lu AA37096 in order to investigate safety, tolerability and the pharmacokinetic profile of the drug in humans. Lu AA37096 has been discovered based on findings with the unique mechanism of action of escitalopram (Cipralex®) but incorporates effects on a number of additional targets in the brain. Lu AA37096 has shown very convincing effects in animal models of mood disorders as well as in pain models.

"Focus at Lundbeck Research is to discover innovative compounds that address unmet needs for patients. Lu AA37096 is an example of a new generation of compounds with a great potential within mood disorders and other indications for which preclinical research has demonstrated significant efficacy," says Peter Høngaard Andersen, Head of Research at Lundbeck.

At the same time Lundbeck has decided to discontinue further development of Lu AA44608 in clinical phase I for the potential treatment of mood disorders.

Other news from the department research and development

Most read news

More news from our other portals

So close that even
molecules turn red...